Show Your Work: D-Wave Opens the Door To Performance Comparisons Between Quantum Computing Architectures
Users can now use IBM’s Qiskit to submit the same problem to the D-Wave Advantage quantum system as well as other gate model systems supported in Qiskit
BURNABY, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- D-Wave Systems Inc., the leader in quantum computing systems, software, and services, today launched a first-of-its-kind cross-system software tool providing interoperability between quantum annealing and gate model quantum computers. The open-source plugin allows developers to easily map quadratic optimization inputs in IBM’s Qiskit™ format onto D-Wave’s quadratic unconstrained binary optimization (QUBO) format and solve the same input on any quantum system supported in Qiskit. The code is available for free as a stand-alone package in GitHub and marks a major industry milestone: the ability to use, test, solve and compare real applications with both gate-model and annealing quantum computers. For the first time, developers and forward-thinking businesses can have a real assessment of the benefits of different systems on their applications.
Interoperability is a critical step in the maturation of transformative technologies. Until now, there hasn’t been a convenient way to send the same problems to solvers on both gate and D-Wave systems, or to obtain head-to-head comparisons of results from the two different quantum computing systems. Before today, using a different quantum computing vendor’s hardware and software required significant investment to familiarize developers with code, solvers, and SDKs.
D-Wave’s industry-first open-source package removes those barriers. Qiskit users can now submit Ising Hamiltonians to the D-Wave quantum computer, in addition to any gate model system Qiskit supports. Now, cross-paradigm transparency and comparison will give quantum developers the flexibility to try different systems, while providing businesses with key insights into performance so they can identify, build, and scale quantum applications.
The company also called for users to publish their work.
“In order for the quantum computing ecosystem to fully mature, the developer and business communities alike need access to diverse quantum systems and the ability to compare cross-architectural performance,” said Alan Baratz, CEO, D-Wave. “The next few years will bring a proliferation of quantum applications, and companies must be able to make informed decisions about their quantum computing investment and initiatives to stay competitive. We’ve moved beyond measures that explore ‘does the system work?’ Instead, enterprises want to benchmark which systems add the most value to their businesses. We’re opening the door to this and we encourage users of the tool to share their work and publish their results.”
The news is in line with D-Wave’s ongoing mission to provide practical quantum computing via access to the most powerful quantum hardware, software, and tools. In 2018, D-Wave brought the Leap™ quantum cloud service and open-source Ocean™ SDK to market. In February 2020, Leap expanded to include new hybrid solver services to solve real-world, business-sized problems. At the end of September, D-Wave made available the Advantage™ quantum system, with more than 5000 qubits, 15-way qubit connectivity, and expanded hybrid solver services that can run problems with up to one million variables. The combination of the computing power of Advantage and the scale to address real-world problems with the hybrid solver services in Leap enables businesses to run performant, real-time, hybrid quantum applications for the first time. And with the new cross-system software tool, now users can benchmark their applications across annealing and gate model systems, to further understand and benefit from performance comparisons.
As part of its commitment to enabling businesses to build in-production quantum applications, the company also introduced D-Wave Launch™, a jump-start program for businesses who want to get started building hybrid quantum applications today but may need additional support.
About D-Wave Systems Inc.
D-Wave is the leader in the development and delivery of quantum computing systems, software and services and is the world’s first commercial supplier of quantum computers. Our mission is to unlock the power of quantum computing for the world. We do this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, cybersecurity, fault detection, and financial modeling. D-Wave’s systems are being used by some of the world’s most advanced organizations, including NEC, Volkswagen, DENSO, Lockheed Martin, USC, and Los Alamos National Laboratory. With headquarters near Vancouver, Canada, D-Wave’s US operations are based in Palo Alto, CA and Bellevue, WA. D-Wave has a blue-chip investor base including PSP Investments, Goldman Sachs, BDC Capital, NEC Corp., and In-Q-Tel. For more information, visit: www.dwavesys.com.
D-Wave Systems Inc.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
REPURCHASE OF SHARES20.1.2021 18:15:00 CET | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 62,790 of its own shares in the period from 14 January 2021 up to and including 20 January 2021 at an average price of €28.52. As announced on 11 November 2020, these repurchases are being made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €1.8 million. The total number of shares purchased under this programme to date is 799,922 shares at an average price of €26.90 for a total consideration of €21.5 million. 2,031,091 shares were held in treasury as at 20 January 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: firstname.lastname@example.org About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding
KONNECT SELECTS SOLUTIONS 30 TO ROLL OUT ITS OFFER IN WESTERN EUROPE20.1.2021 18:00:00 CET | Press release
Solutions 30 (Euronext Paris: S30) has been selected by konnect, an entity of the Eutelsat Group (Euronext Paris: ETL), to roll out its new ultra high-speed satellite Internet access for the general public. As part of this partnership, Solutions 30 will carry out all installation services, allowing konnect to guarantee its customers a professional, uniform, and standardized installation in European countries where its offer is marketed. Europe’s leading provider of rapid-response multi-technology services, Solutions 30 performs more than 60,000 call-outs a day thanks to a team of 11,000 technicians and a particularly dense territorial network in Europe. For more than 15 years, the company has leveraged a unique software platform for team management and call-out optimization to provide customers with a standardized operating process that guarantees service quality and consistency. A significant part of Solutions 30’s business is in telecommunications, where it intervenes on behalf of th
Auction details government bonds20.1.2021 16:20:00 CET | Press release
Auction date January 27, 2021 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2023-11-13 1057 SE0004869071 1.5% 1,5002031-05-12 1062 SE0013935319 0.125% 3,500 Settlement date January 29, 2021 Bids have to be entered by 11.00 on January 27, 2021 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 FO@riksgalden.se
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING20.1.2021 16:20:00 CET | Press release
Bid date, 2021-01-22Bid Submission Date2021-01-22Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-01-26Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-01-27Maximum Allocation25 per cent of Offered AmountAllocation TimeNo later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-01-26Option Repayment Date 12023-01-26Option Repayment Date 22024-01-26Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to email@example.com Stockholm, 2021-01-20 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes20.1.2021 16:07:55 CET | Press release
Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the tria
ArcAroma AB: 210120 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag20.1.2021 16:00:00 CET | Pressemelding
Pressmeddelande 2021-01-20 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag Styrelserna i ArcAroma AB (publ) och OptiFreeze AB (publ) beslutade igår att föreslå ett samgående mellan bolagen genom fusion. Beslutet har tagits mot bakgrund av den marknadspotential och de synergieffekter som identifierats i samband med bolagens utökade samarbetsavtal, som tecknades i november 2020. ArcAroma och OptiFreeze har i olika omfattning samarbetat sedan grundandet av OptiFreeze 2011, där ArcAroma var en av grundarna till OptiFreeze. Sedan bolagens utökade samarbete inleddes i november 2020 har marknadsmöjligheter och synergier framstått som allt tydligare om bolagens resurser och tillväxtpotential kombineras. När fusionen är genomförd är målet att inleda processen för ett listbyte till Nasdaq Stockholm Small Cap. Storleken på det fusionerade bolaget skapar rätt förutsättningar för en kostnadseffektiv accelererad tillväxt som vilar på en unik teknologiplattform. Det nya bolagets kostnad
Equinor ASA: Early Warning Press Release20.1.2021 12:49:07 CET | Press release
Stavanger, Rogaland, Norway, January 20, 2021 – Equinor ASA ("Equinor") (OSE: EQNR, NYSE: EQNR) announces that on January 19, 2021 it disposed of its beneficial ownership of an aggregate of 100,000,000 common shares ("Common Shares") of Athabasca Oil Corporation ("Athabasca"), at a price of C$0.18 per Common Shares, for aggregate gross proceeds of C$18,000,000 (the "Transaction"), through the facilities of the Toronto Stock Exchange on a block trade basis. Immediately prior to the Transaction, Equinor beneficially owned and controlled a total of 100,000,000 Common Shares of Athabasca, representing approximately 18.8% of the issued and outstanding Common Shares of Athabasca. Immediately following the Transaction, Equinor no longer has beneficial ownership and control over any of the issued and outstanding Common Shares of Athabasca. As a result of the Transaction, Equinor's beneficial ownership of Common Shares of Athabasca has decreased to less than 10% of the issued and outstanding Co